| [1] |
Koblizek V, Tomsova M, Cermakova E, et al. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype[J]. Rhinology, 2011, 49(4): 397-406.
|
| [2] |
Han MK, Agusti A, Calverley PM, et al. Wouters the future of COPD[J]. Am J Respir Crit Care Med, 2010, 182(5): 598-604.
|
| [3] |
Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses[J]. Eur Respir J, 2010, 36(3): 531-539.
|
| [4] |
Bakke PS, Rönmark E, Eagan T, et al. Recommendations for epidemiological studies on COPD[J]. Eur Respir J, 2011, 38(6): 1261-1277.
|
| [5] |
Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD. Identification,definition and implications for quidelines[J].Arch Bronchoconeumol, 2012, 48(3): 86-98.
|
| [6] |
Floto RA, Haworth CS. European Respiratory Monograph[M].Sheffield: European Respiratory Society; 2011.
|
| [7] |
Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis[J]. Thorax, 2010, 65(Suppl 1): i1-i59.
|
| [8] |
Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset[J]. Thorax, 2012, 67(3): 238-243.
|
| [9] |
George C, Zermansky W, Hurst JR. Frequent exacerbations in chronic obstructive pulmonary disease[J]. BMJ, 2011, 342: d1434.
|
| [10] |
Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2011, 184(6): 625-626.
|
| [11] |
GINA Board of Directors, GINA Science Committee. Global strategy for asthma management and prevention 2014(revision)[EB/OL].2014.
URL
|
| [12] |
Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease[J]. J Cachexia Sarcopenia Muscle, 2011, 2(2): 81-86.
|
| [13] |
Sanchez FF, Faganello MM, Tanni SE, et al. Anthropometric midarm measurements can detect systemic fat-free mass depletion in patients with chronic obstructive pulmonary disease[J]. Braz J Med Biol Res, 2011, 44(5): 453-459.
|
| [14] |
National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) clinical guidelines CG101[EB/OL].2013.
URL
|
| [15] |
Celli BR. Update on the management of COPD[J]. Chest, 2008, 133(6):1451-1462.
|
| [16] |
Anthoniesen NR, Skeans MA,Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial[J]. Ann Intern Med, 2005, 142(4): 233-239.
|
| [17] |
Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking[J]. BMC Med, 2010, 8: 84.
|
| [18] |
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease(updated 2014)[EB/OL]. 2014.
URL
|
| [19] |
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azitromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis.The BAT randomized controlled trial[J]. JAMA, 2013, 309(12):1251-1259.
|
| [20] |
Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial[J]. Respir Res, 2010, 11(11): 10.
|
| [21] |
Hobbs K, Brown D. Consider adding this drug to Fight COPD that's severe[J]. J Fam Pract, 2012, 61(7): 414-416.
|
| [22] |
Decramer M, Janssens W. Mucoactive therapy in COPD[J]. Eur Respir Rev, 2010, 19(116): 134-140.
|
| [23] |
Duiverman ML, Wempe JB, Bladder G, et al. Two-year home-based nocturnal non-invasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial[J]. Respir Res, 2011, 12:112.
|